Bart W. Faber

4.0k total citations · 1 hit paper
55 papers, 2.7k citations indexed

About

Bart W. Faber is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Immunology. According to data from OpenAlex, Bart W. Faber has authored 55 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Public Health, Environmental and Occupational Health, 17 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Bart W. Faber's work include Malaria Research and Control (32 papers), Mosquito-borne diseases and control (20 papers) and vaccines and immunoinformatics approaches (6 papers). Bart W. Faber is often cited by papers focused on Malaria Research and Control (32 papers), Mosquito-borne diseases and control (20 papers) and vaccines and immunoinformatics approaches (6 papers). Bart W. Faber collaborates with scholars based in Netherlands, France and United Kingdom. Bart W. Faber's co-authors include Edmond J. Remarque, Alan W. Thomas, Clemens H. M. Kocken, Sten Stemme, Olov Wiklund, Jan Holm, Göran K. Hansson, J L Witztum, Simon P. J. Albracht and G.A. Bentley and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Bart W. Faber

54 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.

1995 738 citations Bart W. Faber et al. profile →

Peers

Countries citing papers authored by Bart W. Faber

Since Specialization

Citations

This map shows the geographic impact of Bart W. Faber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart W. Faber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart W. Faber more than expected).

Fields of papers citing papers by Bart W. Faber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart W. Faber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart W. Faber. The network helps show where Bart W. Faber may publish in the future.

Co-authorship network of co-authors of Bart W. Faber

This figure shows the co-authorship network connecting the top 25 collaborators of Bart W. Faber. A scholar is included among the top collaborators of Bart W. Faber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart W. Faber. Bart W. Faber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a Monoclonal Antibody Sandwich ELISA for the Determination of Antigen Content and Quality in Human and Animal Tetanus Vaccines 2024 ·ALTEX ·(unknown), (unknown), (unknown), Peter Rigsby, (unknown), Maxime Vermeulen, (unknown), Bart W. Faber, Paul Stickings	0
2	Plasmodium falciparum AMA1 and CSP antigen diversity in parasite isolates from southern Ghana 2024 ·Frontiers in Cellular and Infection Microbiology ·Kwadwo Asamoah Kusi, Linda Eva Amoah, Festus K. Acquah, (unknown), (unknown), (unknown), (unknown), Eric Kyei‐Baafour, Frank Osei, (unknown), Susheel Kumar Singh, Michael Theisen, Edmond J. Remarque, Bart W. Faber, María Belmonte, Harini Ganeshan, Jun Huang, Eileen Villasante, Martha Sedegah	1
3	E. coli production process yields stable dengue 1 virus-sized particles (VSPs) 2020 ·Vaccine ·(unknown), Bart W. Faber, James E. Crowe, Babs E. Verstrepen, (unknown)	8
4	Amyloid-like Behavior of Site-Specifically Citrullinated Myelin Oligodendrocyte Protein (MOG) Peptide Fragments inside EBV-Infected B-Cells Influences Their Cytotoxicity and Autoimmunogenicity 2018 ·Biochemistry ·(unknown), (unknown), Nico J. Meeuwenoord, Nicole Heijmans, (unknown), (unknown), Bart W. Faber, Bert A. ‘t Hart, Sander I. van Kasteren	10
5	Cross-reactivity between apical membrane antgen 1 and rhoptry neck protein 2 in P. vivax and P. falciparum: A structural and binding study 2017 ·PLoS ONE ·B. Vulliez-Le Normand, Frederick Saul, Sylviane Hoos, Bart W. Faber, G.A. Bentley	19
6	Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial 2017 ·Vaccine ·Sodiomon B. Sirima, Christine Durier, (unknown), Sophie Houard, Adama Gansané, Pierre Loulergue, Mathilde Bahuaud, Nadine Benhamouda, Issa Nébié, Bart W. Faber, Edmond J. Remarque, Odile Launay, Espérance Ouédraogo, Guillaume Sanou, Sonia Guéguen, (unknown), (unknown), Clemens H. M. Kocken, Frédéric Batteux, Éric Tartour	30
7	Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein 2016 ·The Journal of Immunology ·S. Anwar Jagessar, Inge R. Holtman, Sam Hofman, Elena Morandi, Nicole Heijmans, Jon D. Laman, Bruno Gran, Bart W. Faber, Sander I. van Kasteren, Bart J. L. Eggen, Bert A. ‘t Hart	40
8	Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation 2016 ·PLoS ONE ·Bart W. Faber, Stephan Hellwig, Sophie Houard, (unknown), Jürgen Drossard, (unknown), (unknown), (unknown), Richard Byrne, (unknown), (unknown), Alan W. Thomas, Clemens H. M. Kocken, Edmond J. Remarque	6
9	Structural and Functional Insights into the Malaria Parasite Moving Junction Complex 2012 ·PLoS Pathogens ·B. Vulliez-Le Normand, Michelle L. Tonkin, Mauld H. Lamarque, (unknown), Sylviane Hoos, (unknown), Frederick Saul, Bart W. Faber, G.A. Bentley, Martin J. Boulanger, Maryse Lebrun	115
10	Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques 2011 ·Malaria Journal ·Muzamil Mahdi Abdel Hamid, Edmond J. Remarque, (unknown), (unknown), David L. Narum, Alan W. Thomas, Clemens H. M. Kocken, Walter R. Weiss, Bart W. Faber	10
11	A multi‐bioreactor system for optimal production of malaria vaccines with Pichia pastoris 2011 ·Biotechnology Journal ·Jens Fricke, (unknown), (unknown), Roman Lang, Bart W. Faber, R. Luttmann	18
12	Immunization with different Pf AMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits 2011 ·Malaria Journal ·Kwadwo Asamoah Kusi, Bart W. Faber, (unknown), Alan W. Thomas, Clemens H. M. Kocken, Edmond J. Remarque	17
13	A novel method to clean protein G agarose for affinity column matrix with renewed binding capacity and high IgG selectivity 2009 ·Journal of Immunological Methods ·(unknown), Edmond J. Remarque, Bart W. Faber, Alan W. Thomas	3
14	Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris 2008 ·Vaccine ·Bart W. Faber, Edmond J. Remarque, Clemens H. M. Kocken, (unknown), (unknown), (unknown), (unknown), Michèle Haumont, Søren Jepsen, Odile Leroy, Alan W. Thomas	28
15	Crystal Structure of the Malaria Vaccine Candidate Apical Membrane Antigen 1 2005 ·Science ·J.C. Pizarro, B. Vulliez-Le Normand, Marie-Laure Chesne-Seck, Christine R. Collins, Chrislaine Withers‐Martinez, Fiona Hackett, Michael J. Blackman, Bart W. Faber, Edmond J. Remarque, Clemens H. M. Kocken, Alan W. Thomas, G.A. Bentley	162
16	Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites 2005 ·Molecular and Biochemical Parasitology ·Marie-Laure Chesne-Seck, J.C. Pizarro, B. Vulliez-Le Normand, Christine R. Collins, Michael J. Blackman, Bart W. Faber, Edmond J. Remarque, Clemens H. M. Kocken, Alan W. Thomas, G.A. Bentley	79
17	Structural differences between the ready and unready oxidized states of [NiFe] hydrogenases 2005 ·JBIC Journal of Biological Inorganic Chemistry ·Anne Volbeda, Lydie Martin, Christine Cavazza, Michael H. Matho, Bart W. Faber, Winfried Roseboom, Simon P. J. Albracht, Elsa D. Garcin, Marc Rousset, Juan C. Fontecilla‐Camps	255
18	Quantitative amino acid analysis of bovine NADH:ubiquinone oxidoreductase (Complex I) and related enzymes. Consequences for the number of prosthetic groups 2003 ·Biochimica et Biophysica Acta (BBA) - Bioenergetics ·Simon P. J. Albracht, Eddy van der Linden, Bart W. Faber	26
19	Purification and Characterization of Benzoate-para-hydroxylase, a Cytochrome P450 (CYP53A1), from Aspergillus niger 2001 ·Archives of Biochemistry and Biophysics ·Bart W. Faber, R.F.M. van Gorcom, (unknown)	50
20	The [NiFe] hydrogenase from Allochromatium vinosum studied in EPR-detectable states: H/D exchange experiments that yield new information about the structure of the active site 2001 ·JBIC Journal of Biological Inorganic Chemistry ·Boris Bleijlevens, Bart W. Faber, Simon P. J. Albracht	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact